Evidence map›Paper›PMID 36831273›Full record

ArticleCells2023

Hodgkin Lymphoma Cell Lines and Tissues Express mGluR5: A Potential Link to Ophelia Syndrome and Paraneoplastic Neurological Disease.

Sofia Schnell, Ellen Knierim, Petra Bittigau, Jakob Kreye, Kathrin Hauptmann, Patrick Hundsdoerfer, Susanne Morales-Gonzalez, Markus Schuelke, Marc Nikolaus

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Cells, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06958341 (Registry for Patients With Antibody-mediated Neuroimmunological Diseases), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06958341 recruitingnot on this map

Registry for Patients With Antibody-mediated Neuroimmunological Diseases

TypeobservationalSponsorCharite University, Berlin, GermanyRan2021 to 2031Enrolled300ConditionsEncephalopathy, Psychosis, Impaired Consciousness, Epilepsy
3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Sofia SchnellNeuroCure Cluster of Excellence, Charité-Universitätsmedizin Berlin, 10117 Berlin, Germany.
Ellen KnierimNeuroCure Cluster of Excellence, Charité-Universitätsmedizin Berlin, 10117 Berlin, Germany.
Petra BittigauDepartment of Neuropediatrics, Charité-Universitätsmedizin Berlin, 10117 Berlin, Germany.
Jakob KreyeDepartment of Neuropediatrics, Charité-Universitätsmedizin Berlin, 10117 Berlin, Germany.ORCID 0000-0003-2913-1015
Kathrin HauptmannInstitute of Pathology, Charité-Universitätsmedizin Berlin, 10117 Berlin, Germany.ORCID 0000-0003-0590-3674
Patrick HundsdoerferHelios Klinikum Berlin-Buch, Kinder-und Jugendmedizin, 13125 Berlin, Germany.
Susanne Morales-GonzalezNeuroCure Cluster of Excellence, Charité-Universitätsmedizin Berlin, 10117 Berlin, Germany.
Markus SchuelkeNeuroCure Cluster of Excellence, Charité-Universitätsmedizin Berlin, 10117 Berlin, Germany.ORCID 0000-0003-2824-3891
Marc NikolausNeuroCure Cluster of Excellence, Charité-Universitätsmedizin Berlin, 10117 Berlin, Germany.
Charité - Universitätsmedizin Berlin · DEBerlin Institute of Health at Charité - Universitätsmedizin Berlin · DEGerman Center for Neurodegenerative Diseases · DEHelios Hospital Berlin-Buch · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ophelia syndrome is characterized by the coincidence of severe neuropsychiatric symptoms, classical Hodgkin lymphoma, and the presence of antibodies to the metabotropic glutamate 5 receptor (mGluR5). Little is known about the pathogenetic link between these symptoms and the role that anti-mGluR5-antibodies play. We investigated lymphoma tissue from patients with Ophelia syndrome and with isolated classical Hodgkin lymphoma by quantitative immunocytochemistry for mGluR5-expression. Further, we studied the L-1236, L-428, L-540, SUP-HD1, KM-H2, and HDLM-2 classical Hodgkin lymphoma cell lines by FACS and Western blot for mGluR5-expression, and by transcriptome analysis. mGluR5 surface expression differed significantly in terms of receptor density, distribution pattern, and percentage of positive cells. The highest expression levels were found in the L-1236 line. RNA-sequencing revealed more than 800 genes that were higher expressed in the L-1236 line in comparison to the other classical Hodgkin lymphoma cell lines. High mGluR5-expression was associated with upregulation of PI3K/AKT and MAPK pathways and of downstream targets (e.g.,

Indexed as

EncephalitisHodgkin DiseaseNervous System DiseasesAutoantibodiesCell LineHumansPhosphatidylinositol 3-KinasesReceptor, Metabotropic Glutamate 5SyndromeAutoantibodiesPhosphatidylinositol 3-KinasesReceptor, Metabotropic Glutamate 5anti-mGluR5 encephalitisHodgkin lymphomametabotropic glutamate 5 receptorneuroimmunologyOphelia syndromepediatric neurologypediatric oncologytranscriptome analysis

Identifiers

PMID36831273
PMCPMC9953995
OpenAlexW4320491871

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.